Healthcare resource utilization and costs associated with inflammatory bowel disease among patients with chronic inflammatory diseases: a retrospective cohort study
Abstract Background Chronic inflammatory diseases (CIDs; ankylosing spondylitis [AS], psoriatic arthritis [PsA], psoriasis [PsO], or rheumatoid arthritis [RA]) and inflammatory bowel disease (IBD; Crohn’s disease and ulcerative colitis) are associated with substantial economic burden. The relative i...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2020-04-01
|
| Series: | BMC Rheumatology |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s41927-020-0115-2 |
| _version_ | 1819016941049741312 |
|---|---|
| author | David P. Hudesman Soumya D. Chakravarty Bruno Emond Lorie A. Ellis Patrick Lefebvre Kay Sadik Jose U. Scher |
| author_facet | David P. Hudesman Soumya D. Chakravarty Bruno Emond Lorie A. Ellis Patrick Lefebvre Kay Sadik Jose U. Scher |
| author_sort | David P. Hudesman |
| collection | DOAJ |
| description | Abstract Background Chronic inflammatory diseases (CIDs; ankylosing spondylitis [AS], psoriatic arthritis [PsA], psoriasis [PsO], or rheumatoid arthritis [RA]) and inflammatory bowel disease (IBD; Crohn’s disease and ulcerative colitis) are associated with substantial economic burden. The relative increased costs among patients with CIDs and concomitant IBD compared to those without IBD is an important consideration when deciding on the clinical management of patient symptoms. Given the increasing use of novel agents for the treatment of CIDs, including those that may increase the risk of IBD in patients with CIDs, the objective of the study was to describe the incidence of IBD and to quantify healthcare resource utilization (HRU) and costs associated with IBD among patients with CIDs. Methods The IBM MarketScan® Research Databases (1/2010–7/2017) were used to identify adult patients with ≥2 claims with a diagnosis of either AS/PsA/PsO/RA (index date was a random claim for AS/PsA/PsO/RA). The one-year incidence rate of IBD was calculated following the index date. HRU and healthcare costs were compared between patients developing and not developing IBD in the year following the index date, adjusting for baseline characteristics. Results A total of 537,450 patients with CIDs (mean age = 54.0 years; 63.1% female) were included in the study. The 1-year incidence rate of IBD was 0.52% (range = 0.39% in patients with PsO but without PsA to 1.73% in patients with AS). Patients who developed IBD (N = 2778) had significantly higher rates of inpatient, outpatient, and emergency room visits (incidence rate ratios [IRR] = 2.91, 1.35, 1.81; all P < 0.0001), compared to patients without IBD (N = 534,672). Patients who developed IBD had $18,500 (P < 0.0001) higher total costs per year, including $15,121 (P < 0.0001) higher medical costs and $3380 higher pharmacy costs (P < 0.0001). Conclusion Higher HRU and costs were observed in patients with concomitant CID and IBD compared to patients with CID alone. Consideration should be given to treatment decisions that adequately manage CID and IBD to ensure optimal clinical and economic outcomes. |
| first_indexed | 2024-12-21T02:55:37Z |
| format | Article |
| id | doaj.art-bcbb661d25e443bba9217df50f4dcc9c |
| institution | Directory Open Access Journal |
| issn | 2520-1026 |
| language | English |
| last_indexed | 2024-12-21T02:55:37Z |
| publishDate | 2020-04-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Rheumatology |
| spelling | doaj.art-bcbb661d25e443bba9217df50f4dcc9c2022-12-21T19:18:20ZengBMCBMC Rheumatology2520-10262020-04-014111310.1186/s41927-020-0115-2Healthcare resource utilization and costs associated with inflammatory bowel disease among patients with chronic inflammatory diseases: a retrospective cohort studyDavid P. Hudesman0Soumya D. Chakravarty1Bruno Emond2Lorie A. Ellis3Patrick Lefebvre4Kay Sadik5Jose U. Scher6NYU Langone HealthJanssen Scientific AffairsAnalysis Group, Inc.Janssen Scientific AffairsAnalysis Group, Inc.Janssen Scientific AffairsNYU Langone HealthAbstract Background Chronic inflammatory diseases (CIDs; ankylosing spondylitis [AS], psoriatic arthritis [PsA], psoriasis [PsO], or rheumatoid arthritis [RA]) and inflammatory bowel disease (IBD; Crohn’s disease and ulcerative colitis) are associated with substantial economic burden. The relative increased costs among patients with CIDs and concomitant IBD compared to those without IBD is an important consideration when deciding on the clinical management of patient symptoms. Given the increasing use of novel agents for the treatment of CIDs, including those that may increase the risk of IBD in patients with CIDs, the objective of the study was to describe the incidence of IBD and to quantify healthcare resource utilization (HRU) and costs associated with IBD among patients with CIDs. Methods The IBM MarketScan® Research Databases (1/2010–7/2017) were used to identify adult patients with ≥2 claims with a diagnosis of either AS/PsA/PsO/RA (index date was a random claim for AS/PsA/PsO/RA). The one-year incidence rate of IBD was calculated following the index date. HRU and healthcare costs were compared between patients developing and not developing IBD in the year following the index date, adjusting for baseline characteristics. Results A total of 537,450 patients with CIDs (mean age = 54.0 years; 63.1% female) were included in the study. The 1-year incidence rate of IBD was 0.52% (range = 0.39% in patients with PsO but without PsA to 1.73% in patients with AS). Patients who developed IBD (N = 2778) had significantly higher rates of inpatient, outpatient, and emergency room visits (incidence rate ratios [IRR] = 2.91, 1.35, 1.81; all P < 0.0001), compared to patients without IBD (N = 534,672). Patients who developed IBD had $18,500 (P < 0.0001) higher total costs per year, including $15,121 (P < 0.0001) higher medical costs and $3380 higher pharmacy costs (P < 0.0001). Conclusion Higher HRU and costs were observed in patients with concomitant CID and IBD compared to patients with CID alone. Consideration should be given to treatment decisions that adequately manage CID and IBD to ensure optimal clinical and economic outcomes.http://link.springer.com/article/10.1186/s41927-020-0115-2Inflammatory bowel diseaseCrohn’s diseaseUlcerative colitisPsoriasisPsoriatic arthritisAnkylosing spondylitis |
| spellingShingle | David P. Hudesman Soumya D. Chakravarty Bruno Emond Lorie A. Ellis Patrick Lefebvre Kay Sadik Jose U. Scher Healthcare resource utilization and costs associated with inflammatory bowel disease among patients with chronic inflammatory diseases: a retrospective cohort study BMC Rheumatology Inflammatory bowel disease Crohn’s disease Ulcerative colitis Psoriasis Psoriatic arthritis Ankylosing spondylitis |
| title | Healthcare resource utilization and costs associated with inflammatory bowel disease among patients with chronic inflammatory diseases: a retrospective cohort study |
| title_full | Healthcare resource utilization and costs associated with inflammatory bowel disease among patients with chronic inflammatory diseases: a retrospective cohort study |
| title_fullStr | Healthcare resource utilization and costs associated with inflammatory bowel disease among patients with chronic inflammatory diseases: a retrospective cohort study |
| title_full_unstemmed | Healthcare resource utilization and costs associated with inflammatory bowel disease among patients with chronic inflammatory diseases: a retrospective cohort study |
| title_short | Healthcare resource utilization and costs associated with inflammatory bowel disease among patients with chronic inflammatory diseases: a retrospective cohort study |
| title_sort | healthcare resource utilization and costs associated with inflammatory bowel disease among patients with chronic inflammatory diseases a retrospective cohort study |
| topic | Inflammatory bowel disease Crohn’s disease Ulcerative colitis Psoriasis Psoriatic arthritis Ankylosing spondylitis |
| url | http://link.springer.com/article/10.1186/s41927-020-0115-2 |
| work_keys_str_mv | AT davidphudesman healthcareresourceutilizationandcostsassociatedwithinflammatoryboweldiseaseamongpatientswithchronicinflammatorydiseasesaretrospectivecohortstudy AT soumyadchakravarty healthcareresourceutilizationandcostsassociatedwithinflammatoryboweldiseaseamongpatientswithchronicinflammatorydiseasesaretrospectivecohortstudy AT brunoemond healthcareresourceutilizationandcostsassociatedwithinflammatoryboweldiseaseamongpatientswithchronicinflammatorydiseasesaretrospectivecohortstudy AT lorieaellis healthcareresourceutilizationandcostsassociatedwithinflammatoryboweldiseaseamongpatientswithchronicinflammatorydiseasesaretrospectivecohortstudy AT patricklefebvre healthcareresourceutilizationandcostsassociatedwithinflammatoryboweldiseaseamongpatientswithchronicinflammatorydiseasesaretrospectivecohortstudy AT kaysadik healthcareresourceutilizationandcostsassociatedwithinflammatoryboweldiseaseamongpatientswithchronicinflammatorydiseasesaretrospectivecohortstudy AT joseuscher healthcareresourceutilizationandcostsassociatedwithinflammatoryboweldiseaseamongpatientswithchronicinflammatorydiseasesaretrospectivecohortstudy |